For many cancer patients, the road to a precise diagnosis often begins with a tissue biopsy—an invasive procedure that can be physically taxing and, in some cases, surgically tricky to perform. However, the shift toward “liquid biopsies,” which seek the same critical genetic data from a simple blood draw, is gaining momentum. The latest move in this space comes from Caris Life Sciences, which has officially applied for authorization to bring its blood-based molecular profiling test to patients in New York.
The submission to the New York State Department of Health (NYSDOH) marks a strategic attempt by the Irving, Texas-based company to enter one of the most strictly regulated healthcare markets in the United States. The test, known as Caris Assure, is designed to analyze the genetic makeup of a tumor by sequencing circulating nucleic acids in the blood, potentially offering a less invasive alternative for biomarker analysis.
While the company already operates under federal CLIA certification and CAP accreditation, New York maintains its own rigorous oversight through the Clinical Laboratory Evaluation Program (CLEP). For a biotech firm, clearing the New York hurdle is often viewed as a “gold standard” of validation, signaling that a test meets stringent requirements for analytical validity and quality systems before it can be used on specimens originating within the state.
The New York Regulatory Gauntlet
Unlike many other states that rely primarily on federal standards, New York requires clinical laboratories to undergo a separate, comprehensive review administered through the Wadsworth Center. This process is not a mere formality. it is a deep dive into the laboratory’s permits, the qualifications of its personnel, and the empirical evidence supporting the test’s accuracy.
The CLEP review process focuses on several critical pillars:
- Analytical Validation: Proving the test consistently and accurately detects the genetic markers it claims to find.
- Quality Systems: Ensuring the laboratory has rigid protocols to prevent errors in sample handling and data reporting.
- Personnel Qualifications: Verifying that the scientists and pathologists overseeing the tests meet state-mandated expertise levels.
- Regulatory Compliance: Confirming all operations align with New York’s specific public health laws.
Because this review is currently underway, Caris Assure is not yet authorized for use on patients in New York. The company is effectively in a waiting period, pending a determination from the NYSDOH.
Breaking Down the Science: What is cNAS?
To understand why Caris Assure is significant, one must understand the difference between traditional sequencing and circulating nucleic acids sequencing (cNAS). Most traditional biopsies look at a static piece of tissue. CNAS, however, looks at the fragments of DNA and RNA that tumors shed into the bloodstream.
Caris Assure doesn’t just look at a few targeted markers; it analyzes the “whole exome” (the protein-coding regions of the DNA) and the “whole transcriptome” (the RNA) across approximately 22,000 genes. This provides a more holistic view of the tumor’s evolution and how it might respond to specific drugs.
| Marker Analyzed | Clinical Significance |
|---|---|
| Tumor Alterations | Identifies specific mutations that can be targeted by precision drugs. |
| MSI & TMB | Helps determine if a patient is a fine candidate for immunotherapy. |
| Pharmacogenomics | Predicts how a patient’s body will metabolize specific medications. |
| Clonal Hematopoiesis | Distinguishes between tumor-derived mutations and age-related blood mutations. |
Who Stands to Benefit?
The primary stakeholders in this regulatory push are the patients and oncologists within New York State. For a patient with a tumor in a hard-to-reach location—such as the lung or brain—a blood-based test can provide critical data without the risks associated with invasive surgery. For the oncologist, the ability to monitor a tumor’s genetic shifts in real-time via blood draws allows for more agile adjustments to treatment plans.
From a business perspective, Caris Life Sciences (NASDAQ: CAI) is looking to expand its footprint in a high-density medical hub. New York is home to some of the world’s leading cancer centers; gaining authorization there not only opens a massive patient market but also provides the company with high-level clinical validation that can be leveraged in other global markets.
Constraints and Uncertainties
Despite the potential, the path forward is not guaranteed. The NYSDOH is known for its exacting standards, and there is no predetermined timeline for when the Wadsworth Center will complete its review. The commercial success of Caris Assure will depend heavily on third-party payer reimbursement. Even if the state authorizes the test, doctors and patients will need insurance coverage to make the technology accessible.
Disclaimer: This article is for informational purposes only and does not constitute medical advice, diagnosis, or investment recommendation. Always seek the advice of a physician or other qualified health provider with any questions regarding a medical condition.
The next critical checkpoint for Caris Life Sciences will be the official determination from the New York State Department of Health. Until the CLEP authorization is granted, the company cannot legally perform Caris Assure testing on specimens collected from New York residents. Investors and healthcare providers are now awaiting the results of the Wadsworth Center’s formal review.
Do you think blood-based profiling will eventually replace tissue biopsies entirely? Share your thoughts in the comments or share this story with your network.
